Persistence Market Research is released upcoming report on title "Neuropathic Pain Market: Global Industry Analysis and Forecast 2014 - 2020".
New York, NY -- (SBWIRE) -- 03/02/2015 -- Neuropathic pain results from damage or dysfunction of the peripheral and central nervous system (CNS). Pain can develop after injury to any level of the nervous system. Some of the major syndromes include postherpetic neuralgia, painful traumatic mononeuropathy, root avulsions, painful polyneuropathy, central pain syndromes, postsurgical pain syndromes, and complex regional pain syndrome. Most commonly prescribed medications for neuropathic pain include antidepressants (also known as tricyclic antidepressants), anticonvulsants (also called neuroleptic medications), and anesthetics. Major antidepressants include Nortriptiline and Amitriptyline. Carbamazepine, Valproic Acid, Felbamate, Clonazepam, and Phenytoin are the most commonly used anticonvulsants for the treatment of neuropathic disorders. Major anesthetics used to reduce neuropathic pain are Tocainide or Mexiletine and Idocaine. Antidepressants and anticonvulsants are the first line of treatment for neuropathic pain. The combination of these two medications is thought to be particularly effective in the treatment of neuropathic pain.
Buy Full Report: http://www.persistencemarketresearch.com/market-research/neuropathic-pain-market.asp
The global neuropathic pain market is categorized based on various forms of neuropathic pain and their therapeutics. Based on types, the report covers postherpetic neuralgia, painful diabetic neuropathy, and trigeminal neuralgia. The drug segment is further sub-segmented into antidepressants, cannabinoids, dietary supplements, neuromodulators, anticonvulsants topical treatments, N-methyl-D-aspartate (NMDA) antagonism, opioids, and topical agents.
In terms of geography, North America dominates the global neuropathic pain market. This is due to increased awareness about neuropathic pain disorders and technological advancements in diagnostic procedures in the region. The U.S. represents the largest market for neuropathic pain in North America, followed by Canada. In Europe, Germany, France, the U.K., Italy, and Spain account for a major share of the neuropathic pain market. The market in Asia is expected to expand at a significant rate over the next five years. This is due to various companies setting up manufacturing facilities in the region. Moreover, increasing awareness about neuropathic pain disorders and rise in geriatric population are also driving the growth of the market in the region. India, China and Japan are expected to be the fastest growing neuropathic pain markets in Asia.
In recent times, increased demand for diagnostic and therapeutic products to manage neuropathic pain disorders is the key driver of the global neuropathic pain market. Increased investments in R&D in the pharmaceutical sector and introduction of innovative drugs have also fueled the growth of this market. Ongoing development of drugs with properties such as improved safety and high patient compliance are also supporting the growth of the pain market. Therapies, such as biological therapy and physiotherapy have immense potential to spur the growth of this market.
However, stringent regulations by various governments hamper the growth of the global neuropathic pain market. Moreover, the patent expiry of some blockbuster drugs (drugs that have an annual sale of USD 1.0 million and above) and risk of complications and side-effects associated with antidepressants and anticonvulsants have hindered the growth of the market. Increasing mergers and acquisitions of drug manufacturing companies and rapid product launches are some of the major trends in the global neuropathic pain market.
The major companies operating in this market are Convergence Pharmaceuticals, Daiichi Sankyo Company, Limited, Janssen Pharmaceuticals, Inc., Endo Pharmaceuticals Inc., Grünenthal GmbH, Amgen Inc., Baxter Healthcare Corporation, Biogen Idec, Inc., Bristol-Myers Squibb, Eli Lilly and Company, GE Healthcare, GlaxoSmithKline plc, Pfizer Inc., Sanofi S.A., and Teva Pharmaceutical Industries Ltd.
Request Full Toc: http://www.persistencemarketresearch.com/toc/4149
Key points covered in the report:
1) Report segments the market on the basis of types, application, products, technology, etc (as applicable)
2) The report covers geographic segmentation
3) The report provides the market size and forecast for the different segments and geographies for the period of 2010 to 2020
4) The report provides company profiles of some of the leading companies operating in the market
The report also provides porters five forces analysis of the market.
Visit our blog at: http://pmrblog.com/
About Persistence Market Research
Persistence Market Research (PMR) is a U.S.-based full-service market intelligence firm specializing in syndicated research, custom research, and consulting services. PMR boasts market research expertise across the Healthcare, Chemicals and Materials, Technology and Media, Energy and Mining, Food and Beverages, Semiconductor and Electronics, Consumer Goods, and Shipping and Transportation industries. The company draws from its multi-disciplinary capabilities and high-pedigree team of analysts to share data that precisely corresponds to clients' business needs.
PMR stands committed to bringing more accuracy and speed to clients' business decisions. From ready-to-purchase market research reports to customized research solutions, PMR's engagement models are highly flexible without compromising on its deep-seated research values.